Valuation Cocrystal Pharma, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-20 EDT			5-day change	1st Jan Change
0.9429 ^USD	-0.39%		-11.05%	-3.69%

09-09	Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment	CI
08-17	Cocrystal Pharma, Inc. Announces Appointment of Carol Brosgart, Md to Board of Directors, Effective August 12, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	63.35	15.88	17.52	20.55	13.49	18.23	-	-
Change	-	-74.94%	10.34%	17.29%	-34.34%	35.12%	-	-
Enterprise Value (EV)	63.35	15.88	17.52	20.55	13.49	18.23	18.23	18.23
Change	-	-74.94%	10.34%	17.29%	-34.34%	35.12%	0%	0%
P/E	-4.06x	-0.41x	-0.92x	-1.17x	-1.26x	-1.31x	-1.99x	-1.5x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0x	0x	0.15x	0x	0.19x	0.1x	-0x
Capitalization / Revenue	-	-	-	-	-	0.17x	-	-
EV / Revenue	-	-	-	-	-	0.17x	-	-
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	-0x	-0x	-0x	-1.55x	-1.67x	-1.28x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-1.92	-4.77	-1.87	-1.72	-0.78	-0.725	-0.475	-0.63
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	-	-	-	-	-	110	-	-
EBITDA	-	-	-18.37	-	-	-	-	-
EBIT ¹	-14.22	-38.83	-18.56	-17.88	-9.019	-11.8	-10.9	-14.2
Net income ¹	-14.18	-38.84	-17.98	-17.5	-8.831	-11.66	-10.75	-13.9
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	7.8000	1.9500	1.7222	2.0200	0.9790	0.9466	0.9466	0.9466
Nbr of stocks (in thousands)	8,122	8,143	10,174	10,174	13,784	19,263	-	-
Announcement Date	3/23/22	3/29/23	3/28/24	3/31/25	3/31/26	-	-	-